s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals. The stock NMRA was on track for ...

For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...

Cybin (CYBN) announced the launch of its first strategic partnership agreement with Segal Trials in furtherance of Cybin’s multinational ...

A Cleveland Clinic psychiatrist discusses what the latest research suggests causes bipolar, what the individual experiences, ...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 m ...

“Looking ahead, we are excited about Cybin’s next phase of investigation and growth and for the upcoming milestones, including a readout of topline efficacy data from our CYB004 Phase 2 GAD study in ...

Arrivo BioVentures today announced positive data from its SP-624-103 study evaluating the impact of SP-624's novel epigenetic mechanism of action on neurological pathways. The findings provide ...

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder ...

bringing us markedly closer to our goal of addressing the unmet needs of patients living with depression worldwide." ABX-002 is also being evaluated in the company's ongoing AMPLIFY Phase 2 trial as ...

Ketamine, a hallucinogenic drug approved as an anesthetic, has been used to treat adults with depression, PTSD and other conditions, and studied in youth with depression.

Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study, sending shares of the company down 82% in premarket trading. The ...

(NASDAQ:NMRA), a $1.7 billion market cap biopharmaceutical company focused on brain disease treatments, disclosed that its Phase 3 KOASTAL-1 Study of navacaprant did not meet the primary endpoint for ...